# Ethris

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ethris

- Industry: Biotechnology
- Headquarters: Planegg, Germany
- Website: www.ethris.com
- Total disclosed funding: $61M
- Latest round: Debt (Sep 14, 2026)
- Investors on record: 3

## About

Established in 2009 and based in Planegg, Germany, Ethris GmbH operates as a biotechnology company that provides transformative messenger RNA (mRNA) enable to develop discover, and design therapeutic antibodies. In February 2025, Ethris GmbH received USD 5 million of grant funding from new investor Coalition for Epidemic Preparedness Innovations. As of 2022, Carsten Rudolph is the CEO of Ethris. The company has developed a proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA) platform and uses its other proprietary technology platforms to generate protein replacement therapy candidates focusing on rare genetic disorders. Ethris is advancing a novel class of mRNA products for respiratory and infectious diseases as well as prophylactic vaccines. Thus, tackling influenza, COVID-19, and other seasonal respiratory viruses. Ethris' therapeutic programs include ETH47 – Influenza & SARS-CoV-2, ETH42 – Primary ciliary dyskinesia, and ETH45 – Pulmonary alveolar proteinosis. Additionally, its vaccine programs include mucosal vaccines, multivalent vaccines, mutation-agnostic vaccines, ETH49 – Hepatitis C, and ETH50 – Betacoronavirus. The company plans to use the February 2025 funding to support its product research and development.

## Funding rounds

- Debt, Sep 14, 2026, $35M — European Investment Bank
- Series B, Feb 1, 2022, $27M — Laureus Capital
- Series A, Dec 31, 2011 — HS LifeSciences

## Investors

- HS LifeSciences (https://capitalatlas.ai/funds/hs-lifesciences) — Series A
- Laureus Capital (https://capitalatlas.ai/funds/laureus-capital) — Series B
- European Investment Bank (https://capitalatlas.ai/funds/european-investment-bank) — Debt